|Articles|April 14, 2020

Report: Infants with COVID-19 Experience Mild Symptoms in China

Author(s)Rachel Lutz

Among 4 babies born with coronavirus in Wuhan, China, 1 had no noticeable symptoms.

None of the 4 newborn babies identified in China who developed coronavirus disease 2019 (COVID-19) required intensive care or mechanical ventilation, according to a paper published in the European Respiratory Journal.

Investigators from Wuhan University identified novel coronavirus infections in newborns in order to describe the clinical features, treatment, outcomes, and intrauterine transmission potential. Wuhan was the initial epicenter of the pandemic outbreak, which has now spread throughout much of the world, and the city is slowly trying to return to a new normal. The investigators wrote that in the early days of the pandemic, older adults were reported to be more frequently infected; however, there have since been reports of pediatric and infant cases.

From December 8, 2019 through March 13, 2020 there were 81,026 cases of COVID-19 and 4 cases were among infants, the study authors reported. The infants’ ages ranged from 30 hours to 17 days old and 3 were males, the authors added.

The cases were confirmed through nucleic acid detection using nasopharyngeal swabs in 2 babies, while the other 2 received anal swabs. Three infants underwent CT scans and they all showed increased lung marking, the study authors said.

Of the four, 2 newborns had fever, 1 had shortness of breath, 1 had cough and 1 had no noticeable symptoms.

Disease onset occurred in the hospital for 2 babies and at home for the remaining 2 babies. Half were in isolation and the other half were not at the time of disease onset, the study authors continued. Time between dates of admission and symptoms to diagnosis was between 0 and 2 days.

All of the babies received supportive treatment, though none required stay in the intensive care unit or mechanical ventilation. None of the infants had any severe complications.

The hospital stays for each of the 3 newborns who were deemed recovered (after 2 consecutive nucleic acid tests done 24 hours apart) were 16, 23, and 30 days, respectively.

All 4 of the babies were born via C-section and 3 of them were separated from their mothers right after being born. They were not breastfed. The fourth baby was not separated from

the mother at birth and was breastfed for 16 days until symptom onset, according to the study authors.

All 4 of the babies’ mothers were determined to have COVID-19, according to the investigators, with 3 of the mothers showing symptoms prior to delivery and 1 developing symptoms after delivery. The most common symptoms exhibited by the mothers were fever, cough, appetite decline and oil intolerance. Each of the mothers also underwent CT scans (3 before and 1 after delivery), where they each had abnormal findings.

“It is encouraging that newborn babies and infants appear to be less vulnerable to SARS-CoV-2,” the study authors said.

“On the other hand, mild or no symptoms in the youngest make it difficult to detect and prevent further transmission.”

While there were 4 infections in newborns younger than 28 days in this study, the investigators said there were 9 babies with COVID-19 aged between 28 days and 1 year.

Therefore, the infection rate might be slightly higher proportionately in newborns than in infants. Transmission may be different, such as intrauterine transmission, which these findings support, the study authors said.

“The chance of infection through ways other than intrauterine transmission is deemed to be low,” they said, after outlining that all the babies were delivered via C-section and 3 were separated from their mothers. But they admitted that nosocomial infection could not be ruled out entirely, and said that nasopharyngeal and anal swabs cannot directly indicate intrauterine infection.

“Newborn babies are susceptible to SARS-CoV-2 infection,” the study authors concluded. “The symptoms in newborn babies were milder and outcomes were less severe as compared to adults.”


Related to this article

Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Measles Update: October 9, 2026
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
FAQ: What You Need to Know About Measles in 2026
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.